A randomized phase II clinical trial in NSCLC combining SBRT and I.V. anti-PD-1 with or without I.T. anti-CTLA-4/anti-PD-L1 plus CD1c+ myDC

Project Details

Description

We propose to perform a randomized phase II clinical trial in patients with oligometastatic non-small-cell lung cancer (NSCLC). NSCLC patients are eligible for this clinical trial when failed to respond or progress on anti-PD-1 therapy (pembrolizumab, with or without cytotoxic chemotherapy).
AcronymFWOTBM3
StatusActive
Effective start/end date1/10/1930/09/23

Flemish discipline codes

  • Clinical trials

Keywords

  • NSCLC